Aims & Scope – Current Neurovascular Research

Aims & Scope:

 

Current Neurovascular Research provides a cross platform for the publication of scientifically rigorous research that addresses disease mechanisms of both neuronal and vascular origins in neuroscience. The journal serves as an international forum publishing novel and original work as well as timely neuroscience research reviews in the disciplines of cell developmental disorders, plasticity, and degeneration that bridges the gap between basic science research and clinical discovery. Current Neurovascular Research emphasizes the elucidation of disease mechanisms, both cellular and molecular, which can impact the development of unique therapeutic strategies for neuronal and vascular disorders.

 

cnr-flyer.jpg

For more details, please visit: https://benthamscience.com/journals/current-neurovascular-research/aims-scope/#top

Most Accessed Articles – Positron Emission Tomography and Autoradiography Imaging of P-selectin Activation Using 68Ga-Fucoidan in Photothrombotic Stroke

Author(s): Ina Israel, Felix Fluri, Fabian Schadt, Andreas K. Buck, Samuel Samnick*.

Abstract:

Background: P-selectin is activated early after stroke, followed by a rapid decline. This time course can be used to generate important information on stroke onset. The latter is crucial for therapeutic decision-making of wake-up strokes (i.e. thrombolysis or not). Here, we evaluated the specific p-selectin inhibitor fucoidan labeled with gallium-68 (68Ga-Fucoidan) as an imaging biomarker for assessing p-selectin activation in acute ischemic stroke using Positron Emission Tomography (PET).

Methods: 68Ga-Fucoidan was investigated in rats brain at 2-5 h (n=16), and additionally at 24-26 h (n=9) and 48 h (n=3) after induction of photothrombic stroke or in sham-operated animals (n=6). Correlation of cerebral 68Ga-Fucoidan uptake with p-selectin expression was determined by exposing freshly cut brain cryosections to autoradiography and immunostaining using specific antibodies against p-selectin.

Results: PET scans showed an increased accumulation of 68Ga-Fucoidan in the histologically proven ischemic stroke, as compared to the corresponding contralateral hemisphere in all except one animal. The median ratio between the uptake in the ischemic lesion and the contralateral region was 1.95 (1.45-2.41) at 2-5 h, 1.38 (1.05-1.89) at 24-26 h, and 1.09 (0.81-1.38) at 48 h after stroke, compared to 1.22 (0.99-1.49) for sham-operated animals. In the ex vivo autoradiography, 68Ga-Fucoidan accumulation co-localized with p-selectin as assessed by immunostaining. Control animals and those scanned at 24-26 h and 48 h after stroke exhibited no elevated 68Ga-Fucoidan uptake in either hemisphere.

Conclusion: PET imaging using 68Ga-Fucoidan represents a valuable tool for assessing p-selectin activation in vivo discriminating ischemic stroke early after stroke onset.

 

 

For more details, please visit: http://www.eurekaselect.com/160550

Open Access Articles – A Novel Neuroimaging Model to Predict Early Neurological Deterioration After Acute Ischemic Stroke

Journal Name: Current Neurovascular Research

Author(s): Yen-Chu Huang*, Yuan-Hsiung Tsai, Jiann-Der Lee, Jen-Tsung Yang, Yi-Ting Pan.

Abstract:

Objective: In acute ischemic stroke, early neurological deterioration (END) may occur in up to one-third of patients. However, there is still no satisfying or comprehensive predictive model for all the stroke subtypes. We propose a practical model to predict END using magnetic resonance imaging (MRI).

Method: Patients with anterior circulation infarct were recruited and they underwent an MRI within 24 hours of stroke onset. END was defined as an elevation of ≥2 points on the National Institute of Health Stroke Scale (NIHSS) within 72 hours of stroke onset. We examined the relationships of END to individual END models, including: A, infarct swelling; B, small subcortical infarct; C, mismatch; and D, recurrence.

Results: There were 163 patients recruited and 43 (26.4%) of them had END. The END models A, B and C significantly predicted END respectively after adjusting for confounding factors (p=0.022, p=0.007 and p<0.001 respectively). In END model D, we examined all imaging predictors of Recurrence Risk Estimator (RRE) individually and only the “multiple acute infarcts” pattern was significantly associated with END (p=0.032). When applying END models A, B, C and D, they successfully predicted END (p<0.001; odds ratio: 17.5[95% confidence interval: 5.1– 60.8]), with 93.0% sensitivity, 60.0% specificity, 45.5% positive predictive value and 96.0% negative predictive value.

Conclusion: The results demonstrate that the proposed model could predict END in all stroke subtypes of anterior circulation infarction. It provides a practical model for clinical physicians to select high-risk patients for more aggressive treatment to prevent END.

For more details, please visit: http://www.eurekaselect.com/162202

EDITOR’S CHOICE ARTICLE –Preparation, Characterization and In vitro Biological Activity of Soyasapogenol B Loaded onto Functionalized Multi-walled Carbon Nanotubes

Journal Name: Current Bioactive Compounds

Author(s): Ahmed A. Haroun*, Hala A. Amin, Sameh H. Abd El-Alim.

 

 

 

Graphical Abstract:

 

 

Abstract:

Background: Using Multi-Walled Carbon Nanotubes (MWCNTs) as a drug delivery system, can avoid the need for solvents and preventing drug precipitation in aqueous solution. Soyasapogenol B (SSB) acts as an important therapeutic agent owing to its numerous reported biological activities. Hence, this work deals with preparation and characterization of SBB loaded onto functionalized MWCNTs with tetraethyl orthosilicate (TEOS) and/or chitosan.

Method: SSB was immobilized onto functionalized MWCNTs using miniemulsion technique. Moreover, niosomes were utilized to encapsulate the prepared systems. The formulations were analyzed by Fourier Transform Infrared Spectroscopy (FTIR), Transmission Electron Microscope (TEM) and particle size distribution analysis. In vitro release profiles of loaded SSB particles were carried out and kinetics of release were also studied. In vitro cytotoxicity of the prepared materials was examined and evaluated by SRB assay using different human cell lines such as normal melanocytes (HFB4), and carcinoma breast and liver (MCF7 and HepG2, respectively) in comparison with the standard doxorubicin.

Results: SSB loaded materials exhibited successful encapsulation in niosomes, resulting in sustainable in drug release. Study of kinetics of release revealed presence of several complex factors affecting SSB release. Mathematical processing of the in vitro release data showed that the release of SSB from niosomal formulations obeyed more than one model. The second order and Higuchi’s models were the most fitting models in case of presence of chitosan or TEOS, respectively. While, all formulations exhibited low cytotoxic properties on all tested cell lines.

Conclusion: FTIR, particle size and TEM analysis confirmed that SSB was successfully loaded onto functionalized MWCNTs. Moreover, the different niosome formulations based on functionalized MWCNTs were prepared with sustainable SSB release in. The cytotoxicity could be minimized in case of chitosan and TEOS functionalization.

 

For more details, please visit: http://www.eurekaselect.com/151456/article

ARTICLE TO READ ON WORLD STROKE DAY, 2018!

Neuropharmacological Actions of Metformin in Stroke

 

Author(s): Jia Jia, Jian Cheng, Jingshu Ni, Xuechu Zhen.

 

 

 

Graphical Abstract:

 

 

 

Abstract:

Increasing epidemiologic evidence suggests that metformin, a well-established AMPK activator and the most favorable first-line anti-diabetic drug, reduces stroke incidence and severity. However, the mechanism for this remains unclear. Moreover, previous experimental studies have reported controversial results about the effects of metformin on stroke outcomes during the acute phase. However, recent studies have consistently suggested that AMPK-mediated microglia/macrophage polarization and angioneurogenesis may play essential roles in metformin-promoted, long-term functional recovery following stroke. The present review summarizes the neuropharmacological actions of metformin in experimental stroke with an emphasis on the recent findings that the cell-specific effects and duration of AMPK activation are critical to the effects of metformin on stroke outcomes.

 

For more details, please visit: http://www.eurekaselect.com/128222

World Stroke Day, 2018!

 

world-stroke-day-bentham-science-avail-discount-banner-3

Around 80 million people living in the world today have experienced a stroke and over 50m survivors live with some form of permanent disability as a result. While for many, life after stroke won’t be quite the same, with the right care and support living a meaningful life is still possible. As millions of stroke survivors show us every day, it is possible to get #UpAgainAfterStroke.

 

Bentham Science publishes articles related to World Stroke Day in its Subscription based journals including:

 

TO AVAIL 20% DISCOUNT ON RELATED EBOOKS, KINDLY VISIT: HTTPS://EBOOKS.BENTHAMSCIENCE.COM/

 

BENTHAM SCIENCE MEDIA PARTNERSHIP FOR “6th World Congress on Controversies, Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD)”

 

6th World Congress on Controversies, Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD)

(Thursday  8 November  2018  4:00 PM  –  Saturday  10 November  2018 6:00 PM)

IN 13 DAYS

 

 

20% DISCOUNTS ON PURCHASING EBOOKS AND SUBSCRIPTIONS ON JOURNALS FROM BENTHAM SCIENCE TO DELEGATES ATTENDING THE CONFERENCE 

TO AVAIL, QUOTE “BSPCNF18” AT WWW.EUREKASELECT.COM OR EMAIL AT MARKETING@BENTHAMSCIENCE.ORG 

 

 

Conference Website: https://bit.ly/2yE5mZX

EDITOR’S CHOICE ARTICLE – Microbial Biofilm and Quorum Sensing Inhibition: Endowment of Medicinal Plants to Combat Multidrug-Resistant Bacteria

Journal Name: Current Drug Targets

Author(s): Rina Das, Dinesh Kumar Mehta*.

 

 

 

Graphical Abstract:

 

Abstract:

 

Continued emergence and spread of multidrug-resistant bacteria behooved the development of alternative treatment strategies, including antimicrobial drugs. A hopeful approach is to target cellto- cell communications, commonly known as quorum-sensing (QS) and microbial biofilm formation. Quorum Sensing is a method used on bacteria to determine their physiological behavior and coordinate gene expression based on the cell to cell signaling. Many physiological functions of bacteria are controlled by quorum sensings such as virulence, motility, sporulation, luminescence, and biofilm formation. Microbial biofilms are organized aggregations of cells attached to a substratum and surrounded by a self-produced extrapolymeric substance (EPS) matrix. Currently, biofilm formation and quorum sensing are considered as a prospective novel target for antimicrobial therapy to control multidrug- resistant infections. Plant-based natural products have been comprehensively studied in this context. In this review, a comprehensive overview of various research papers published in the last decade on plant-derived molecules that are capable of inhibiting quorum sensing or microbial biofilm formation is reviewed, mentioning the biosynthetic classes of active compounds and their biological activity in the performed assays.

 

For more details, please visit: http://www.eurekaselect.com/161075/article

New Issue :: Micro and Nanosystems (Volume: 10, Issue: 1)

 

Micro and Nano-systems publishes significant original work, topical reviews and guest edited issues ranging from technologies and systems to product innovation and new manufacturing processes with features at the micro and nanoscale. Applications for micro and nano-systems in areas such as health, environment, food, security and consumer goods are covered. The topics to be addressed include lab-on-a-chip, microfluidics, nano-biotechnology, micro and nano manufacturing, printed electronics and MEMS.

 

mns

 

Articles from the journal Micro and Nanosystems Volume 10, Issue 1:

 

For details on the articles, please visit this link ::  https://bit.ly/2OTrpC5

 

 

 

Aims & Scope – Current Pharmaceutical Biotechnology

Aims & Scope

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:

  • DNA/protein engineering and processing
  • Synthetic biotechnology
  • Omics (genomics, proteomics, metabolomics and systems biology)
  • Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
  • Drug delivery and targeting
  • Nanobiotechnology
  • Molecular pharmaceutics and molecular pharmacology
  • Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
  • Pharmacokinetics and pharmacodynamics
  • Applied Microbiology
  • Bioinformatics (computational biopharmaceutics and modeling)
  • Environmental biotechnology
  • Regenerative medicine (stem cells, tissue engineering and biomaterials)
  • Translational immunology (cell therapies, antibody engineering, xenotransplantation)
  • Industrial bioprocesses for drug production and development
  • Biosafety
  • Biotech ethics

Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.

Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

 

cpb-flyer

 

For more details, please visit: https://benthamscience.com/journals/current-pharmaceutical-biotechnology/aims-scope/#top